LOADING
Comparing NVIDIA Corporation (NVDA) and Merck & Company (MRK) across the Technology and Health Care sectors. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | NVDA | MRK |
|---|---|---|
| Price | -- | -- |
| Change Today | +0.00% | +0.00% |
| Market Cap | $5.47T | $280.2B |
| P/E Ratio | 46.1 | 32.0 |
| Forward P/E | 26.5 | 22.0 |
| PEG Ratio | 0.68 | 5.18 |
| EPS | $4.90 | $3.55 |
| Revenue Growth (YoY) | 73.2% | 4.9% |
| Profit Margin | 55.6% | 13.6% |
| Return on Equity | 101.5% | 18.9% |
| Dividend Yield | 0.02% | 2.92% |
| Beta | 2.24 | 0.20 |
| 52-Week High | $236.54 | $124.22 |
| 52-Week Low | $129.13 | $71.76 |
| Volume | -- | -- |
NVIDIA Corporation is the larger company by market capitalization. Merck & Company trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. Merck & Company offers a higher dividend yield for income investors. NVIDIA Corporation has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.